A series of preclinical studies show that a new compound, SHP1705, targets circadian clock proteins hijacked by glioblastoma stem cells, impairing the cancer cells’ ability to survive and grow. SHP1705 is also the first clock-targeting compound to complete a phase 1 clinical trial, where it was found to be safe and well-tolerated in humans. Glioblastoma is the most common cancerous brain tumor in adults—and one of the most difficult to treat. Most patients receive a combination of surgery, radiation and chemotherapy, but tumors typically return and resist further treatment. Circadian clock proteins, which regulate the body’s sleep-wake cycle and other daily rhythms at the cellular level, offer a potential solution. Glioblastoma cells hijack these proteins in order to replicate, so switching them off could slow or halt tumor growth. Through a series of biochemical, cellular and animal studies, the researchers tested SHP1705’s ability to neutralize glioblastoma stem cells, finding it to be highly effective. A phase 1 clinical trial led by Synchronicity Pharma, a biotechnology startup that Kay co-founded, showed that SHP1705 was well-tolerated in humans.

An innovative outbreak detection program that tracks disease-causing viruses in wastewater identified the measles virus in Houston samples collected in early January 2025, before cases were reported.

The American Federation for Aging Research (AFAR), is proud to recognize the outstanding contributions of Lauren Hunt, PhD, RN, FNP, with the 2025 Terrie Fox Wetle Rising Star Award in Health Services and Aging Research.

Colorectal cancer is the second leading cause of cancer-related death globally.

Although some of the molecular changes associated with colorectal cancer are known, how they contribute to cancer development is not yet well defined.

In a study published in Journal of Clinical Investigation, researchers used mouse models and studies of colorectal cancer tissues to show that loss of SOX9 gene promotes tumor progression and the pathway it regulates can be a potential target for future treatments.

About The Study: This cross-sectional study of U.S. medical student matriculants found a decrease in the number of matriculants who were first-generation. These students were at significant risk of attrition from medical school, particularly when considering the intersectionality with low-income and underrepresented in medicine identities. These results suggest a need to recruit and retain these students, so that the physician workforce better reflects the backgrounds and experiences of the communities served.